The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab.
 
Paola Ghione
No Relationships to Disclose
 
Erel Joffe
Consulting or Advisory Role - AstraZeneca
 
Nadia De Paola
No Relationships to Disclose
 
Timothy Mainardi
No Relationships to Disclose
 
Sarah J. Noor
Consulting or Advisory Role - Kiowa Kirin
 
Sabela Bobillo
No Relationships to Disclose
 
Patricia L. Myskowski
No Relationships to Disclose
 
M. Lia Palomba
Stock and Other Ownership Interests - Seres Therapeutics (I)
Honoraria - Amgen (I); Evelo Therapeutics (I); Flagship Pioneering (I); Jazz Pharmaceuticals (I); Kite, a Gilead company (I); Merck (I); Novartis (I); Seres Therapeutics (I); Therakos (I)
Consulting or Advisory Role - Merck; Pharmacyclics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics (I); Seres Therapeutics (I)
 
Alison J. Moskowitz
Honoraria - Seagen
Consulting or Advisory Role - ADC Therapeutics; Bristol-Myers Squibb; Cell Medica; Erytech Pharma; Kiowa Kirin; miRagen; Seagen; Takeda
Research Funding - Bristol-Myers Squibb; Kiowa Kirin; miRagen; Seagen
 
Anthony R. Mato
Consulting or Advisory Role - Abbvie/Genentech; Adaptive Biotechnologies; Celgene; Janssen Oncology; Loxo; PER; Pharmacyclics; Prime Oncology; Sunesis Pharmaceuticals; TG Therapeutics; Verastem; Verastem
Research Funding - Abbvie/Genentech; Adaptive Biotechnologies; BeiGene; Genentech; LOXO; Pharmacyclics; Regeneron; Sunesis Pharmaceuticals; TG Therapeutics; Verastem
Travel, Accommodations, Expenses - Pfizer; TG Therapeutics
Other Relationship - Celgene; TG Therapeutics
 
Fushen Sha
No Relationships to Disclose
 
Gottfried Von Keudell
Consulting or Advisory Role - Bayer; Genentech
 
David J. Straus
Honoraria - Elsevier; Seagen
Consulting or Advisory Role - Elsevier; Seagen
 
Ariela Noy
Consulting or Advisory Role - MorphoSys
Speakers' Bureau - Prime Oncology
Research Funding - Pharmacyclics; Rafael Pharmaceuticals
Travel, Accommodations, Expenses - Janssen Oncology; Pharmacyclics
 
Anas Younes
Honoraria - Abbvie; Curis; Epizyme; Janssen; Merck; Roche; Takeda
Consulting or Advisory Role - Bio-Path Holdings, Inc; Celgene; Epizyme; HCM; Roche; Xynomic Pharma
Research Funding - Bristol-Myers Squibb (Inst); Curis (Inst); Genentech (Inst); Janssen (Inst); Merck (Inst); Roche (Inst); Syndax (Inst)
 
Paul A. Hamlin
Consulting or Advisory Role - Celgene; Juno Therapeutics; Karyopharm Therapeutics; Portola Pharmaceuticals
Research Funding - Incyte; Janssen; Molecular Templates; Portola Pharmaceuticals
 
Renier J. Brentjens
Honoraria - Juno Therapeutics
Research Funding - Celgene; Juno Therapeutics
 
Miguel Angel Tejedor-Alonso
No Relationships to Disclose
 
Steven M. Horwitz
Consulting or Advisory Role - ADC Therapeutics; Affimed Therapeutics; Astex Pharmaceuticals; Celgene; Corvus Pharmaceuticals; Innate Pharma; Kura Oncology; Kyowa Hakko Kirin; Millennium; miRagen; Portola Pharmaceuticals; Seagen; Takeda; Verastem
Research Funding - ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Forty Seven (Inst); Kyowa Hakko Kirin (Inst); Seagen (Inst); Takeda (Inst); Trillium Therapeutics (Inst); Verastem (Inst)
 
Andrew David Zelenetz
Stock and Other Ownership Interests - Adaptive Biotechnologies
Honoraria - Clinical Care Options; NCCN; Oncology Information Group; PER
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Cancer Support Community; Celgene; Dava Oncology; Genentech/Roche; Gilead Sciences; Janssen; Karyopharm Therapeutics; Medscape; MEI Pharma; MorphoSys; Novartis; Pfizer; Pharmacyclics; Prime Education; TRM Oncology; Vaniam Group; Verastem
Research Funding - BeiGene; Genentech/Roche; Gilead Sciences; MEI Pharma